Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | STAT1 | P42224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776952 | 0.90 | P2RY12 (0.41) | P2RY12KDM4EALDH1A1HTTMEN1 | |
| SCHEMBL1774791 | 0.88 | ACHE (0.41) | — | |
| SCHEMBL1775983 | 0.87 | HTR2C (0.42) | HTT | |
| Hydrochloric Acid SCHEMBL1774964 | 0.86 | HTR2C (0.42) | HTT | |
| SCHEMBL1774782 | 0.85 | SLC6A7 (0.34) | ALDH1A1FAAHF10TP53 | |
| SCHEMBL1776231 | 0.84 | AKT1 (0.40) | P2RY12ALDH1A1MEN1KMT2A | |
| SCHEMBL1775123 | 0.84 | ALDH1A1 (0.42) | P2RY12KDM4EALDH1A1HTTMEN1 | |
| Hydrochloric Acid SCHEMBL6426380 | 0.84 | KIT (0.39) | — | |
| SCHEMBL1776197 | 0.81 | AKT1 (0.41) | KDM4EALDH1A1HTTKMT2ATSHR | |
| SCHEMBL1776477 | 0.81 | AKT1 (0.40) | KMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | P2RY12 2513/4885KDM4E 2527/4885ALDH1A1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.